Evidence map›Paper›PMID 28889394›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2018

Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum.

Leandro S D'Abronzo, Chong-Xian Pan, Paramita M Ghosh

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Leandro S D'AbronzoVA Northern California Health Care System, University of California at Davis, Sacramento, CA, USA.
Chong-Xian PanVA Northern California Health Care System, University of California at Davis, Sacramento, CA, USA.
Paramita M GhoshVA Northern California Health Care System, University of California at Davis, Sacramento, CA, USA. paghosh@ucdavis.edu.
University of California, Davis · US

Funding

Targeted-and timed-releasing nanotherapeutics against leukemia stem cellsR01CA176803 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PAN, CHONG-XIAN · 2015 to 2019
$1.8M
Rapamycin Regulation of the Androgen Receptor: Implications in Prostate CancerR01CA133209 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GHOSH, PARAMITA M. · 2009 to 2013
$1.1M
(PQD-1) Selective pressure of antiandrogens on castration resistant prostate cancR01CA185509 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GHOSH, PARAMITA M. · 2014 to 2017
$1.0M
Loss of Filamin A Nuclear Localization in Prostate Cancer ProgressionI01BX000400 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI GHOSH, PARAMITA M. · 2011 to 2019
–
Development of targeting nanotherapeutics against bladder cancerI01BX001784 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI PAN, CHONG-XIAN · 2014 to 2017
–
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancerI01BX003840 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI PAN, CHONG-XIAN · 2018 to 2021
–
BLRD VA I01 BX000400BLRD VA I01 BX001784BLRD VA I01 BX003840NCI NIH HHS R01 CA133209NCI NIH HHS R01 CA176803NCI NIH HHS R01 CA185509
6 · The paper itself

Abstract

The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK) consists of four members: EGFR1/ErbB1/HER1, ErbB2/HER2, ErbB3/HER3, and HER4/ErbB4. Signaling through these receptors regulates many key cellular activities, such as cell division, migration, adhesion, differentiation, and apoptosis. The ErbB family has been shown to be overexpressed in different types of cancers and is a target of several inhibitors already in clinical trials. ErbB3 lacks a functional tyrosine kinase domain and therefore has not been as extensively studied as the other members of this family, but its importance in activating downstream pathways, such as the PI3K/Akt pathway, makes this RTK a worthy investigation target, especially in urothelial carcinoma where the PI3K/Akt pathway is vital for progression. In recent times, ErbB3 overexpression has been linked to drug resistance and progression of various diseases, especially cancer. ErbB3 levels in the serum were shown in many cases to be reflective of its role in disease progression, and therefore detection of serum ErbB3 levels during treatment may be of importance.Here we describe two methods for detecting ErbB3 protein in serum from patients who have undergone a clinical trial, utilizing two well-established methods in molecular biology-western blotting and ELISA, focusing on sample preparation and troubleshooting.

Indexed as

Biomarkers, TumorBlotting, WesternDisease ManagementEnzyme-Linked Immunosorbent AssayHumansNeoplasmsProtein IsoformsReceptor, ErbB-3Biomarkers, TumorERBB3 protein, humanProtein IsoformsReceptor, ErbB-3EGFRElisaERBB3SerumUrothelial carcinomaWestern blot

Identifiers

PMID28889394
PMCPMC6481935
OpenAlexW2755137748

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.